The anti-CAPS antibodies and β amyloid as well as amyloid precursor protein markers are promising in Alzheimer’s disease and α-synuclein in Parkinson’s disease. This evidence concerns the gene CAPS and early-onset autosomal dominant Alzheimer disease.